Showing 5231-5240 of 6803 results for "".
- Maintaining Normal Vitamin D Levels May Benefit Melanoma Patients on Immunotherapyhttps://practicaldermatology.com/news/maintaining-normal-vitamin-d-levels-may-benefit-melanoma-patients-on-immunotherapy/2461677/Patients with advanced skin cancer should make extra efforts to maintain normal vitamin D levels when receiving immune checkpoint inhibitors, according to a study in
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation
- Rodan + Fields Gives Back: Company Joins The Recycling Partnershiphttps://practicaldermatology.com/news/rodan-fields-gives-back-company-joins-the-recycling-partnership/2461673/Rodan + Fields, LLC. is joining 80 leading companies to support The Recycling Partnership, a nonprofit organization committed to building a better recycling system. Investing in The Recycling Partnership will help strengthen recycling access, education and infrastructure, advance
- SkinGPT Uses AI to Visualize Long-Term Skincare Benefitshttps://practicaldermatology.com/news/skin-gpt-uses-ai-to-visualize-long-term-skincare-benefits/2461670/Haut.AI is incorporating its new generative AI tech for modeling skin conditions over time. SkinGPT uses AI to create synthetic images and apply skin conditions to input image data. SkinGPT enables users to upload their photos and apply AI to
- Skin Cancer Foundation Hits the Road: Destination Healthy Skin Program Kicks Off on May 6, 2023https://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road-destination-healthy-skin-program-kicks-off-on-may-6-2023/2461669/The Skin Cancer Foundation will launch its annual mobile education and screening program, Destination Healthy Skin, on Saturday, May 6, in Greenwich, Connecticut. The program educates the public about the importance of skin cancer early detection and effective sun p
- Melanoma Research Alliance, Bimini Bay Outfitters Join Forces to Advance Researchhttps://practicaldermatology.com/news/melanoma-research-alliance-bimini-bay-outfitters-join-forces-to-advance-research/2461667/The Melanoma Research Alliance and Bimini Bay Outfitters, a leader in high-performance outdoor apparel, are partnering to accelerate research into melanoma and promote sun safety among outdoor enthusiasts. Alongside a series of educational content rolling out from both organizatio
- AARS Shines Light on Antibiotic Resistance During Rosacea Awareness Monthhttps://practicaldermatology.com/news/aars-shines-light-on-antibiotic-resistance-during-rosacea-awareness-month/2461664/The American Acne and Rosacea Society (AARS) is calling on patients and prescribers to ensure appropriate use of antibiotics to manage rosacea during Rosacea Awareness Month. “It has been well known for many years that dermatologists prescribe more antibiotics per clinician than p
- Adding New Personalized Vaccine to Immunotherapy Slashes Risk for Melanoma Recurrencehttps://practicaldermatology.com/news/adding-new-personalized-vaccine-to-immunotherapy-slashes-risk-for-melanoma-recurrence/2461662/Adding an experimental mRNA vaccine to immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared with immunotherapy alone, a new clinical trial shows. The phase 2b trial results were presented at the annual meeting of the American A
- FDA Clears New Underarm Sweat Control Patchhttps://practicaldermatology.com/news/fda-clears-new-underarm-sweat-control-patch/2461660/The U.S. Food and Drug Administration (FDA) has cleared cleared Brella, the first 3-Minute SweatControl Patch to significantly reduce excessive underarm sweating in adults with primary axillary hyperhidrosis. The Brella SweatControl Patch provide
- News You Can Use: BI Receives Permanent J-Code (J1747) for SPEVIGO Injectionhttps://practicaldermatology.com/news/news-you-can-use-bi-receives-permanent-j-code-j1747-for-spevigo-injection/2461649/The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1747) for Boehringer Ingelheim’s SPEVIGO (spesolimab-sbzo) Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. The J-code for SPEVIGO became eff